Related by context. All words. (Click for frequent words.) 86 Initiates Phase II 85 Initiates Clinical 84 Completes Patient Enrollment 84 Initiate Phase 84 Initiates Phase 84 Commences Phase 83 Initiates Clinical Trial 83 Meets Primary Endpoint 83 Initiates Phase III 82 Phase 2b Clinical Trial 82 Presents Positive 82 Files IND 81 Receives Orphan Drug Designation 81 Initiates Enrollment 81 Completes Enrollment 81 Initiates Phase 2b 80 Begins Dosing 80 Pivotal Phase 80 Presents Preclinical Data 79 Drug Candidate 79 Phase 2b Trial 79 Completes Dosing 79 Clinical Trial Results 79 Phase 2a Trial 79 Granted Orphan Drug 79 Demonstrates Significant 78 Prolongs Survival 78 Metastatic Melanoma 78 Present Preclinical Data 78 Submits NDA 78 Novel Oral 78 Phase IIb Trial 78 Receives Milestone Payment 78 Initiate Clinical Trial 78 Patient Enrollment 77 Phase III Pivotal 77 Phase IIb Clinical Trial 77 Pivotal Phase III 77 Hsp# Inhibitor 77 Presents Positive Preclinical 77 Trial Evaluating 77 Initiates Dosing 77 Phase III Clinical Trial 77 Lupus Drug 77 Submits IND 77 Phase IIa Clinical Trial 77 First Patient Enrolled 77 Lung Cancer Drug 77 Presents Preclinical 77 Oral Calcitonin 77 Phase 1b Clinical Trial 77 Randomized Phase 77 Initiate Phase III 77 Anti Tumor 76 Collaborators Present 76 Phase III Trial 76 Achieves Primary Endpoint 76 Files Investigational 76 Confirmatory Phase 76 Initiates Clinical Trials 76 Announces Initiation 76 Commence Phase 76 Drug Fails 76 Licenses Novel 76 Receives Orphan Drug 76 JAK2 Inhibitor 76 Single Dose 76 Reports Preclinical Data 76 Preclinical Data 76 Dose Ranging Study 76 Therapeutic Competitors Companies 76 Combination REOLYSIN R 76 Demonstrates Positive 76 Study Evaluating 76 IND Application 76 Pooled Analysis 76 FDA Okays 76 Announce Initiation 75 HDAC Inhibitor 75 Receives Approvable Letter 75 Phase 2a Clinical Trial 75 Immunotherapeutic 75 Receives Fast Track 75 Therapeutic Antibody 75 FDA Approvals 75 Protease Inhibitor 75 Submits Biologics License Application 75 NDA Submission 75 Multiple Ascending Dose 75 Kinase Inhibitor 75 Drug Shows Promise 75 Investigational Treatment 75 Diabetic Foot Ulcer 75 Submits Response 75 Develop Novel 75 BioSante Pharmaceuticals Announces 75 Phase Ib Clinical Trial 75 Clinical Trial Evaluating 75 Oral Fingolimod 75 Commences Phase III 75 Receive Milestone Payment 75 Immunomedics Announces 75 Shows Promise Against 75 FDA Accepts 75 Gout Drug 75 Tyrosine Kinase Inhibitor 75 Investigational Drug 75 IND Filing 75 Earns Milestone Payment 74 Randomized Phase II 74 Shows Promising 74 Adjuvant Treatment 74 Confirms Efficacy 74 FDA Clears 74 Prostate Cancer Vaccine 74 Initiated Phase 74 Advanced Melanoma 74 Antitumor Activity 74 Transdermal Patch 74 Shows Efficacy 74 Investigational Compound 74 HCV Protease Inhibitor 74 Improves Survival 74 Vaccine Adjuvant 74 Submits Application 74 Announce Collaboration Agreement 74 Milestone Payment 74 Enrolls First 74 Announce License Agreement 74 Vascular Disrupting Agent 74 Demonstrates Potential 74 Rheumatoid Arthritis Drug 74 Hormone Refractory Prostate Cancer 74 Pulmonary Arterial Hypertension 74 Collaborators Publish 74 Dose Ranging 74 Second Pivotal Phase 74 Systemic Delivery 74 RNAi Therapeutic 74 Pivotal Study 74 Phase III Trials 74 Significantly Improves 74 Proven Effective 74 Preclinical Study 74 Sapacitabine 74 Phase III Clinical Trials 74 JAK Inhibitor 73 Phase 2b Study 73 Demonstrates Statistically Significant 73 Announces Poster Presentations 73 Teva Provides Update 73 Demonstrates Sustained 73 Aflibercept 73 Patients Treated With 73 Novel Antibiotic 73 Announces FDA Clearance 73 Severe Sepsis 73 Develops Novel 73 Demonstrates Efficacy 73 MKC# MT 73 PRN FDA Approves 73 Preclinical Models 73 Improves Outcomes 73 Announces Publication 73 Pivotal Trials 73 Disease Modifying 73 First Patient Dosed 73 Adjunctive Therapy 73 Announces Presentation 73 Bosutinib 73 Nicotine Vaccine 73 Gets FDA Clearance 73 Multicenter Phase 73 Demonstrates Potent 73 Initiate Phase II 73 Receives CE Marking 73 Diabetic Neuropathy 73 Pharmacokinetic Study 73 Therapeutic Competitors companiesandmarkets.com adEgemonye 73 Cites Positive 73 Investigational Oral 73 Therapeutic Competitors Report 73 ARRY # 73 Monoclonal Antibody 73 RNAi Therapeutics 73 Arthritis Drug 73 Recombinant Human 73 Reveals Positive 73 Fast Track Status 73 Small Molecule 73 pralatrexate injection folate analogue 73 Dose Escalation 73 Psoriasis Drug 73 non nucleoside inhibitor 73 Announces Tentative Approval 72 Migraine Drug 72 Combination Treatment 72 initiated Phase Ib 72 Efficacy Trial 72 Therapeutic Vaccine 72 Receives Complete Response 72 Spectrum Pharmaceuticals Announces 72 Ozarelix 72 Hematological Malignancies 72 Fungal Infections 72 Novel Therapeutic 72 Extends Collaboration 72 Epilepsy Drug 72 VentiRx Pharmaceuticals 72 Crofelemer budesonide foam 72 Personalized Immunotherapy 72 Novel Compound 72 Taro Receives 72 Treatment Naïve 72 Anticancer Agent 72 Potent Inhibitor 72 Receives SFDA Approval 72 Demonstrated Significant 72 Shows Statistically Significant 72 Randomized Double blind 72 Randomized Double Blind 72 Parathyroid Hormone 72 Pafuramidine 72 Clinical Trial Data 72 Anticancer Drug 72 Receives Favorable 72 Completes Patient Enrolment 72 Pivotal Trial 72 Files Patent Application 72 Announce Merger Agreement 72 Study Demonstrates 72 Synthetic Peptide 72 Submits Investigational 72 Biomarker Study 72 Plaque Psoriasis 72 Treating Chronic 72 First Patient Treated 72 Aurora Kinase 71 Double Blind Placebo 71 FDA APPROVES 71 Osteoporosis Drug 71 Receptor Agonist 71 Safinamide 71 Novel Vaccine 71 Antibody Drug Conjugate 71 Prospective Randomized 71 Schizophrenia Drug 71 Schizophrenia Treatment 71 Begins Shipment 71 Ceflatonin R 71 Receives NASDAQ 71 II Clinical Trial 71 Pegloticase 71 Identifies Potential 71 Novel Inhibitor 71 FOLOTYN ® 71 Pivotal Phase II 71 Previously Treated 71 Regains NASDAQ 71 Inc Therapeutic Competitors 71 Ebola Vaccine 71 Treated Patients 71 Anti CD# Antibody 71 Sangamo BioSciences Announces 71 pharmacogenomic translational research 71 Clinical Study Shows 71 Elagolix 71 Commercialize Novel 71 Chronic Hepatitis C 71 anti botulism antibody 71 Patient Enrolment 71 Long Term Efficacy 71 Proves Effective 71 Metabolic Disorder 71 Romidepsin 71 Investigational Agent 71 Expands Scientific Advisory 71 Renal Cancer 71 Hematological Cancers 71 Aeolus Pharmaceuticals Announces 71 Tezampanel 71 DOR BioPharma Announces 71 Milestone Payment From 71 Clinical Evaluation 71 Mylan Receives Approval 71 Study Showed 71 Achieves Milestone 71 Patients Receiving 71 Oral Formulation 71 Adjuvant Chemotherapy 71 ALTROPANE R 71 Phase III multicenter 71 Controlled Trial 71 Testosterone MDTS ® 71 oral prodrug 71 Vaccine Protects Against 71 Xcytrin R 71 Anticancer Compound 71 Demonstrate Significant 71 Anti Tumor Activity 71 Generic Versions 71 Clinical Outcome 71 Smallpox Vaccine 71 Receptor Antagonist 71 Receives FDA Clearance 71 Awarded Qualifying Therapeutic 71 Taglich Brothers Initiates Coverage 71 Oral Insulin 71 Rotavirus Vaccine 71 Humanized Anti 71 Transdermal Delivery 71 Mimetics 71 Diamyd Medical Diamyd 71 AVI BioPharma Announces 71 platform HDL Mimetic 70 TELINTRA R 70 Novel Mechanism 70 Forodesine 70 IIa Clinical Trial 70 Patients Enrolled 70 Expanded Indication 70 Lung Cancer Trial 70 Controlled Study 70 Study Shows Benefits 70 Anti Angiogenesis 70 Inflammatory Arthritis 70 ALN HPN 70 Shown Effective 70 Systemic Sclerosis 70 Shows Promise 70 AAG geldanamycin analog 70 Phase #b/#a clinical 70 pan histone deacetylase 70 Pivotal Clinical Trial 70 Hedgehog Pathway Inhibitor 70 Recommends Approval 70 Vaccine Candidate 70 Abstract Accepted 70 TKB# 70 Tuberculosis Vaccine 70 VIVUS Announces 70 Showed Significant 70 Chronic Hepatitis B 70 #-# Full Text 70 Vicriviroc 70 Oral Insulin Capsule 70 Blood Pressure Drug 70 Files Shelf Registration Statement 70 TO AVOID PREGNANCY WHILE 70 Sign License Agreement 70 Receives Positive Opinion 70 Patients Suffering 70 Begins Clinical Trial 70 Significantly Reduces 70 Topline Results 70 Molecular Diagnostic Test 70 Bayer HealthCare Onyx Pharmaceuticals 70 Milestone Payments 70 Inhaled Insulin 70 Mouse Model 70 agonistic human 70 SinuNase TM 70 Placebo Controlled Trial 70 Submits Supplemental 70 PDUFA Date 70 Enzyme Replacement Therapy 70 Signs Merger Agreement 70 Novel Treatments 70 Seasonal Influenza Vaccine 70 Announces Successful Completion 70 Contrast Agents 70 Hepatitis B Vaccine 70 Antithrombin 70 ABLYNX 70 Antiangiogenic 70 Introduces Novel 70 Polymerase Inhibitor 70 Infected Patients 70 Antiviral Activity 70 Sign Licensing Agreement 70 Begin Clinical Trials 70 SPRYCEL ® 70 Amends Agreement 70 Vascular Inflammation 70 Provides Shareholder 70 dependent kinase inhibitor 70 albiglutide 70 Effectively Treats 70 Complicated Skin 70 acetonide FA 70 Bone Metastases 70 GVAX ® 70 Avian Flu Vaccine 70 Antigen Specific 70 See CLINICAL PHARMACOLOGY 70 Crit Rev 70 Slow Progression 70 essential thrombocythemia ET 70 Maribavir 70 Oral Mucositis 70 Prospective Multicenter 70 Tumor Targeting 70 LibiGel ® 70 Relapsed Refractory 70 Efficacy Results 70 Issued Patent 70 Matrix Phase 2b 70 Diabetic Nephropathy 70 Interferon Beta 70 Gastric Cancer 70 Archexin 70 telomerase therapeutic 70 Alvine Pharmaceuticals 70 INSPIRE Trial Phase III 70 REG1 Anticoagulation System 70 Cell Transplants 70 Hepatocellular Carcinoma 70 Intravenous Formulation 70 TB Vaccine 70 Rigel R# 70 Novel Antibody 69 OTC BB PVCT 69 Orally Active 69 Novel Anti Inflammatory 69 Glufosfamide 69 Vitrasert R 69 Bipolar Depression 69 Resistant Hypertension 69 HCV RNA polymerase 69 Supplemental Biologics License Application 69 Replacement Therapy 69 Phase Ib II 69 Ltd Therapeutic Competitors 69 Study Validates 69 Test Detects 69 targeted radiotherapeutic 69 Agonist MABA program 69 oncolytic virus therapies 69 Secures Financing 69 Reacquires 69 Myelodysplastic Syndromes 69 vapreotide acetate 69 Survival Benefit 69 Reduces Mortality 69 Launches Generic Version 69 R lenalidomide 69 Sunesis Pharma 69 Low Dose 69 Refractory Hodgkin Lymphoma 69 Randomized Clinical Trials 69 Licenses Patents 69 Reduces Risk 69 Doripenem 69 Treatment Reduces 69 Announces Licensing Agreement 69 Helps Predict 69 Anticancer Activity 69 Randomized Phase III 69 Potent Antiviral Activity 69 Refractory Angina 69 Obtains Exclusive License 69 lexidronam injection 69 Hematology Molecular Pathology 69 LymphoStat B belimumab 69 SPL# Gel vaginal microbicide 69 Interferon Gamma 69 Announce Licensing Agreement 69 Flamel Technologies Announces 69 Chemotherapeutic Agents 69 Biopharmaceuticals AG 69 Restructures Operations 69 PHASE III 69 vinorelbine tartrate 69 Randomized Study 69 Million Milestone Payment 69 Oral Laquinimod 69 Recurrent Glioblastoma 69 Therapy Improves 69 Janus kinase 69 Successfully Concludes 69 KAI Pharmaceuticals 69 Treatment Naive Patients 69 Silodosin 69 Antifungal 69 Cutaneous T 69 Hypertensive Patients 69 Receives Tentative Approval 69 mGluR2 positive 69 Key Milestones 69 Randomized Controlled 69 EVIZON TM 69 Reduced Risk 69 Combo Therapy 69 Drug Combo 69 MEK Inhibitor 69 Influenza Vaccine Production 69 Factor Receptor 69 Relapsing Multiple Sclerosis 69 antibody MAb 69 Hormone Receptor Positive 69 Newly Diagnosed Multiple Myeloma 69 Cholesterol Drug 69 Boehringer Ingelheim MedImmune 69 Patent Issued 69 MKC# MKC# PP 69 Smooth Muscle 69 Resubmission 69 Osteoporosis Treatment 69 CD# CEA 69 Preclinical Efficacy 69 Patent Covering 69 DP VPA 69 Well Tolerated 69 Postmenopausal Osteoporosis 69 Angiotensin Converting Enzyme 69 Adipose Derived Stem Cells 69 Varespladib 69 J Clin 69 Attenuates 69 selective phosphodiesterase 69 Lupus Nephritis 69 Therapeutic Antibodies 69 humanized interleukin 6 69 Inflammatory Disease 69 Clostridium difficile Infection 69 Board Authorizes 69 Treatment Shows Promise 69 Provides Update Regarding 69 Receives Patent 69 Phase IIA 69 Mg Usa 69 Therapeutic Efficacy 69 Telaprevir VX 69 Data Suggest 69 Guidelines Issued 69 Synta Announces 69 Slows Progression 69 PEGylated Fab fragment 69 drug pipeline TAFA# 69 Subtypes 69 Naive Patients 69 Inhibits 69 SBIR Grant 69 Brentuximab Vedotin SGN 69 Lowers Risk 69 Is Well Tolerated 69 MOVIPREP R 69 Demonstrates Ability 69 orally inhaled migraine 69 PDX pralatrexate 69 Awarded Patents 69 Degarelix 69 Reduces Pain 69 Interferon Alpha 69 Treat Anemia 69 Cholesterol Lowering Drug 69 Granulocyte Colony Stimulating Factor 69 Statistically Significant 69 evaluating mipomersen 69 Generic Version 69 Maven Semantic 69 CCX# B 69 Molecular Diagnostic 69 GATTEX TM 69 Prodrug 69 Optimer Pharma 69 including eniluracil ADH 69 VIVITROL ® 69 AFREZZA TM 69 Mouse Models 69 Inhaled Liposomal Ciprofloxacin 69 Denufosol 69 Ondansetron Orally Disintegrating Tablets 69 Appears Safe 69 Kinase Inhibitors 68 Clinical Trial Enrollment 68 Receptor Antagonists 68 Insulin Glargine 68 Therapeutic Competitors 68 Further Validates 68 AIMM trial 68 Protein Linked 68 Atypical Antipsychotic 68 Atopic Dermatitis 68 Epidermal Growth Factor Receptor 68 2 methoxyestradiol 68 Cancer Stem Cells 68 Malaria Vaccine 68 selective immunoproteasome inhibitor 68 Desvenlafaxine Succinate 68 Acute Heart Failure 68 Obtains Approval 68 multicenter phase 68 Nuvelo Announces 68 Announces License Agreement 68 Exherin 68 Expand Collaboration 68 Metastatic Colorectal Cancer 68 Abiraterone Acetate 68 Neoadjuvant Chemotherapy 68 Panzem R NCD 68 Romiplostim 68 Randomized Trials 68 Develop Innovative 68 Capsules CII 68 Pralatrexate 68 Announces Discontinuation 68 Trandolapril 68 Announces Positive 68 Onyx Pharmaceuticals Announces 68 Anti Inflammatory Drug 68 Metabolic Disease 68 Aloxi ® 68 MBRX 68 TLK# 68 Omacetaxine 68 beta 1a 68 Ridaforolimus 68 personalized dendritic 68 Treatment Resistant 68 R MSCRAMM 68 SinuNase ™ 68 Medoxomil 68 Nasdaq VNDA 68 CYT# potent vascular disrupting 68 Peginterferon Alfa 2a 68 Versus Placebo 68 Cancer Vaccines 68 myelodysplastic myeloproliferative diseases 68 Myoblast 68 receptor tyrosine kinase inhibitor 68 Prove Effective 68 Melphalan 68 Progenitor Cells 68 Left Ventricular Dysfunction 68 Advanced Pancreatic Cancer 68 Significantly Improved 68 Immunomodulatory 68 Iluvien TM 68 Respiratory Virus 68 CRMD# 68 Mycophenolate Mofetil 68 Hydrochlorothiazide Tablets 68 Inhalation Solution 68 Ecallantide 68 Telik Announces 68 Late Breaker 68 treatment naive genotype 68 Patients Treated 68 Pharmaceuticals Initiates 68 Improve Survival 68 Pharmacyclics Announces 68 Plus Ribavirin 68 Chronic Sinusitis 68 Aztreonam Lysine 68 Helps Smokers Quit 68 Intravitreal 68 Recurrent Breast Cancer 68 Vaccine Shows Promise 68 Dose Finding 68 Anemia Drug 68 Novel Therapies 68 Reports Positive 68 XL# XL# 68 Fabry Disease 68 successfully commercialize Iluvien 68 Clinical Efficacy 68 immunosuppressive compound 68 Orphan Status 68 Pandemic Influenza Vaccine 68 orally administered inhibitor 68 Significantly Increases 68 Lenocta TM 68 Non Invasive Treatment 68 Myocardial Ischemia 68 Patient Accrual 68 Improved Survival 68 Transplant Patients 68 Febuxostat 68 Genes Predict 68 Talabostat 68 Gene Linked 68 Curr Opin 68 developing Zerenex ferric 68 Golimumab 68 Completes Previously Announced 68 Valortim TM 68 Myelofibrosis 68 Multicenter Randomized 68 diarrhea predominant irritable 68 HCl Tablets 68 Risperidone Oral Solution 68 Arno Therapeutics 68 Circulating Tumor Cells 68 t2cure GmbH 68 Phase 2a Study 68 Peginterferon alfa 2b 68 Inflammatory Markers 68 toenail onychomycosis 68 Pandemic Influenza Vaccines 68 Lubiprostone 68 Advanced Renal Cell 68 Heart Transplant Recipients 68 hyaluronidase enzyme 68 Glatiramer Acetate 68 CCR5 mAb 68 Dry Powder Inhalers 68 By JENNIFER LEARN 68 Tesetaxel 68 Jumps Higher 68 Myocet 68 MKC# 68 Antitumor 68 Ispinesib SB # 68 Prophylactic Treatment 68 Tyrosine Kinase Inhibitors 68 dasatinib Sprycel ® 68 Oncology Compounds 68 Soft Tissue Sarcoma 68 PHRM 68 KSP inhibitor 68 Proves Successful 68 candidate deforolimus 68 highly selective inhibitor 68 Novel Small Molecule 68 selective A2A adenosine receptor 68 novel orally inhaled 68 refractory chronic lymphocytic 68 Liprotamase 68 Enters Into Collaboration 68 Newly Diagnosed Patients 68 ASX PGL 68 Entry Inhibitor 68 Inhaled Nitric Oxide 68 Panzem R 68 Multiple Sclerosis Rheumatoid Arthritis 68 OvaRex R 68 Receives Funding 68 Pandemic Flu Vaccine 68 Topical Treatment 68 Anti Infective 68 Patient Treated 68 selectin antagonist 68 controlled multicenter Phase 68 Grants Orphan Drug 68 Advanced Colorectal Cancer 68 Malignant Glioma 68 Epratuzumab 68 IG HCR ;) CO 68 Exploit collaboration 68 Lanthanum Carbonate 68 TRANSDUR ™ 68 molecular imaging radiopharmaceutical 68 FDA Approves 68 Secondary Hyperparathyroidism 68 FDA Approves Generic 68 AZX# Phase 68 Chronic Lymphocytic Leukemia CLL 68 Chronic Lymphocytic Leukemia 68 Remission Maintenance 68 HDL Selective Delipidation 68 Prostate Cancer Patients 68 Advanced Prostate Cancer 68 Oral Spray 68 Xeloda ® 68 5 Fluorouracil 68 Bradmer Pharmaceuticals 68 Cetrorelix 68 mertansine 68 Retains CCG Investor Relations 68 FDA Approves Drug 68 Biogen Genentech 68 Male Contraceptive 67 Hepatitis C Virus 67 miconazole Lauriad R 67 Apaziquone 67 Announces Issuance 67 Recombinant Protein 67 AnaSpec Introduces 67 Tramiprosate ALZHEMED TM 67 Peginterferon 67 Receives Positive 67 Nitazoxanide 67 Myelodysplastic Syndrome MDS 67 Restructures Debt 67 diarrhea fatigue asthenia 67 Cardioxyl Pharmaceuticals 67 Sirolimus Eluting Stent 67 RELOVAIR ™ 67 Chronic Renal Failure 67 Antibody Discovery 67 Simulect 67 Medicure Announces 67 Mg Uk 67 Daclizumab 67 Subgroup Analysis 67 Idenix Novartis 67 Integrase Inhibitor 67 Adjuvanted 67 APEX PD 67 Tablet Formulation 67 PANVAC VF 67 Bazedoxifene 67 novel emulsion formulation 67 TRACON Pharmaceuticals 67 Genes Linked 67 Genes Involved 67 TNFerade ™ 67 Randomized Clinical Trial 67 LymphoStat B TM 67 Combination Therapy 67 Regenerative Cell 67 evaluating bafetinib 67 Postdoctoral Position 67 Cloretazine ® 67 Gene Variants 67 Prochymal TM 67 Pharma Merck Serono 67 PF # [002] 67 BiTE Antibody 67 Telik logo TELINTRA 67 Awarded Patent 67 Alnylam Nasdaq ALNY 67 R#/MEM # 67 Patents Covering 67 AUDIO PROVIDED BY 67 candidates Azedra TM 67 markets HP Acthar 67 BioElectronics Corporation Announces 67 includes TOLAMBA TM 67 Shingles Vaccine 67 Microplasmin 67 Aethlon Medical Announces 67 XPEL Announces 67 apricitabine ATC 67 Strengthens Balance Sheet 67 Guidelines Recommend 67 Inc. Nasdaq OXGN 67 MAGE A3 ASCI 67 Obtains License 67 fosbretabulin 67 Study Evaluates 67 Asthma COPD 67 Medullary Thyroid Cancer 67 Hepatitis C Treatment 67 Treatment Experienced 67 Ercole Biotech 67 Hepatitis C Genotype 67 Statin Drugs 67 Rheumatoid Arthritis Patients 67 IL# PE#QQR 67 Trastuzumab DM1 67 Nanoemulsion 67 Ofatumumab 67 evaluating picoplatin 67 Stem Cell Treatment 67 product candidate Lpathomab 67 Elderly Patients 67 Successfully Treated 67 Announces Cancellation 67 Diagnostic Tests 67 SIX RO ROG 67 personalized cellular immunotherapy 67 Node Positive 67 Genes Identified 67 MCSP respectively 67 Kidney Transplant Patients 67 Pharmacokinetics PK 67 Study Shows Significant 67 Neutrolin ® 67 Randomized Placebo controlled 67 TRO# 67 IN PATIENTS WITH 67 Receives Unsolicited 67 SAR# [002] 67 HCV SPRINT 67 2A receptor agonist 67 Levoleucovorin 67 Vaccine Adjuvants 67 Testosterone MDTS R 67 Appoints Experienced 67 Revises FY# Outlook 67 Regenerative Cells 67 Unresectable 67 Nasdaq XTLB 67 Vildagliptin 67 Friedreich Ataxia FRDA 67 Hemodialysis Patients 67 Meta Analysis 67 methylnaltrexone bromide 67 Hospital Acquired Pneumonia 67 oral Janus kinase 67 ThermoDox ® clinical 67 J Am Coll 67 Cervical Dysplasia 67 Signaling Pathway 67 Levels Linked 67 Protein Expression 67 markets Testim ® 67 Tumor Response 67 KRN# 67 ISTODAX ® 67 Study Shows Promise 67 Inflammatory Diseases 67 BRIM2 67 Nipent R 67 GW# [003] 67 Receives Favorable Ruling 67 Pazopanib 67 Nasdaq Deficiency Notice 67 Successfully Treats 67 Panzem ® 67 Testosterone Gel 67 Announces Dosing 67 Secures Additional 67 Receives Approvals 67 Protease Inhibitors 67 Cethromycin 67 Renal Cell Carcinoma 67 Regeneron Pharma 67 Completes Merger With 67 Study Reinforces 67 Proteasome 67 RhuDex 67 Receptor Signaling 67 Benign Prostatic Hyperplasia 67 Receives Conditional 67 compound PMX # 67 Dose Escalation Study 67 Gentamicin Surgical Implant 67 Potentially Fatal 67 Sipuleucel T 67 Angiogenic 67 Antisense Drug 67 Pemphigus Vulgaris 67 Anti Angiogenic 67 Phase III HEAT 67 Predict Risk 67 Extend Collaboration 67 ThermoDox R 67 THERAPEUTICS 67 HER2 Positive 67 LAB CGRP 67 oral salmon calcitonin 67 FDA Panel Recommends 67 DIRECT Trial 67 HuMax TAC 67 Pruvel TM 67 BiovaxID TM 67 Miraculins Announces 67 Dendritic Cells 67 Analytical Tool 67 TRIOLEX ™ 67 Nasdaq ACHN 67 Aganocide 67 Multiple Myeloma Patients 67 Pancreas Cancer Vaccine 67 #:#-#,# CrossRef Medline [002] 67 product platforms AZX# 67 Pirfenidone 67 Invasive Fungal Infections 67 Pediatric Patients 67 Secures Patent 67 P#X# antagonist 67 Modulates 67 Merck Serono Nycomed 67 Heart Failure Patients 67 GVAX R 67 Histone Deacetylase 67 investigational humanized monoclonal antibody 67 Aliskiren 67 oral proteasome inhibitor 67 rasagiline tablets 67 CNS Disorders 67 AMEX RGN 67 Medidur ™ FA 67 forodesine 67 Successfully Completed 67 Oncolytic 67 PNP inhibitor 67 Sustained Reduction 67 Protein Synthesis 67 Quadrivalent 67 Iloperidone 67 Announces Rebranding 67 novel histone deacetylase 67 Visceral Fat 67 novel VDA molecule 67 ASE SVA 67 C1 Inhibitor 67 Aethlon Medical Releases 67 Interferon Alfa 67 estrogen receptor beta agonist 67 LUX Lung 67 include Phenoptin TM 67 Anthracycline 67 Monoclonal Antibodies 67 Virus Linked 67 For Undisclosed Terms